MEDICINOVA, INC. (NASDAQ:MNOV) Files An 8-K Regulation FD Disclosure

Item 7.01

On April 27, 2017 (Japanese Standard Time), MediciNova, Inc. (the
Company) filed with the Tokyo StockExchange a Japanese report
referred to as Kessan Tanshin, which contained the Companys
financial results for the quarter ended March 31, 2017 (the
Tanshin).

The Tanshin is substantially the same as the Companys Quarterly
Report on Form 10-Q for the quarter ended March 31, 2017, except
the following supplemental information is provided:

Expected basic and diluted loss per share for the six months
ending June 30, 2017 is $0.18*

Expected basic and diluted loss per share for the year ending
December 31, 2017 is $0.35*

Note to financial results forecast: The above estimates are based
on certain assumptions made by the Companys management as of the
date hereof. These assumptions are based on managements
experience and perception of current conditions, trends, expected
future developments and other factors believed to be appropriate
in the circumstances. Such estimates are subject to a number of
assumptions, risks and uncertainties, many of which are beyond
the control of the Company and may cause the Companys actual
results to differ materially from the above estimates. Although
the Companys management believes that these assumptions are
reasonable, the Company cannot assure you that the Companys
business will develop in accordance with these estimates.
Investors are cautioned not to rely on these estimates as it is
highly likely that actual results will differ, perhaps
materially. These risks include the risk factors detailed in the
Companys Securities and Exchange Commission filings, including
the Companys Annual Report on Form 10-K for the year ended
December 31, 2016. The Companys independent auditors have not
compiled or been involved in the preparation of the forecasted
financial results for fiscal year 2017. Accordingly, they assume
no responsibility for the accuracy or presentation of this
information.

The information in this Current Report is being furnished and
shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that Section. The
information in this Current Report shall not be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such a filing.

The Tanshin may include forward-looking statements that involve a
number of risks and uncertainties, many of which are beyond the
Companys control. The Companys actual results may differ from
those anticipated or expressed in these forward-looking
statements as a result of various factors, including those set
forth in the Companys Annual Report on Form 10-K for the year
ended December 31, 2016 filed with the Securities and Exchange
Commission and its subsequent periodic reports on Forms 10-Q and
8-K, and the differences may be material. Forward-looking
statements discuss matters that are not historical facts.
Forward-looking statements include discussions regarding our
operating strategy, growth strategy, licensing and acquisition
strategy, cost savings initiatives, industry and economic
conditions, market factors, financial condition, liquidity and
capital resources, results of operations, expected progress of
the development of our product candidates, potential licensing,
collaboration and partnering plans, anticipated trends and
challenges in our business and the markets in which we operate,
competitive position, intellectual property protection, critical
accounting policies and the impact of recent accounting
pronouncements. For example, we make forward-looking statements
regarding the potential for our product candidates to receive
regulatory approval for one or more indications on a timely basis
or at all; the progress and results of pending clinical trials
for certain of our product candidates, including any delays in
commencing or completing enrollment for our ongoing or planned
clinical trials; plans for future clinical trials and regulatory
submissions; unexpected adverse side effects or inadequate
therapeutic efficacy of certain of our product candidates that
could delay or prevent regulatory approval or commercialization
or that could result in product liability claims; other
difficulties or delays in development, testing, manufacturing and
marketing of and obtaining regulatory approval for our product
candidates; the scope and validity of patent protection for our
product candidates; the market potential for our target markets
and our ability to compete; the potential to attract and maintain
relationships with one or more strategic partners and terms of
any related transactions; intense competition if any of our
product candidates are ever commercialized; the potential impact
of uncertainties in the credit and capital markets or a future
deterioration of these markets on our cash reserves; and our
ability to raise sufficient capital or debt financing when
needed, or at all. Such forward-looking statements include
statements preceded by, followed by or that otherwise include the
words may, might, will, intend, should, could, can, would,
expect, believe, estimate, anticipate, predict, potential, plan
or similar words. For all forward-looking statements, we claim
the protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of
1995. You should not rely unduly on these forward-looking
statements, which speak only as of the date on which they are
made. The Company undertakes no obligation to revise or update
publicly any forward-looking statements, whether as a result of
new information, future events or otherwise, unless required by
law.

About MEDICINOVA, INC. (NASDAQ:MNOV)

MediciNova, Inc. is a biopharmaceutical company. The Company is focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Its pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its MN-166 is an oral, anti-inflammatory and neuroprotective agent, which inhibits macrophage migration inhibitory factor (MIF) and certain phosphodiesterases (PDEs). Its MN-001 is an orally bioavailable small molecule compound. Its MN-221 is a highly selective B2-adrenergic receptor agonist being developed for the treatment of acute exacerbations of asthma.

MEDICINOVA, INC. (NASDAQ:MNOV) Recent Trading Information

MEDICINOVA, INC. (NASDAQ:MNOV) closed its last trading session up +0.45 at 6.02 with 158,801 shares trading hands.